Givastomig not checked
I-Mab Biopharma US Limited · TJ033721
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- How it’s given
- “Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), durvalumab, chemotherapy”In the company’s words, NCT04900818 on ClinicalTrials.gov
- Tested for
- Solid Tumor (2 trials), Advanced Cancer (2 trials), Metastatic Cancer (2 trials), Gastric Cancer (2 trials), Gastroesophageal Junction Carcinoma (2 trials), Esophageal Adenocarcinoma (2 trials), PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
- Main trialPhase 2
- “The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer are: * Does the addition of givastomig to standard therapy increase the amount of time that participants survive without progression of their cancer? * What toxicities do participants experience when taking givastomig? Participants may be able to take part in the study if they have unresectable…”In the company’s words, NCT07432295 on ClinicalTrials.gov
- Other names
- TJ033721
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- Mar 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2030 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | |
| Phase 1Recruiting | Dec 2026 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026